Risk factors in pediatric stem cell transplantation for leukemia

Pediatric Transplantation

Volumn 8, Issue 5, 2004, Pages 464-474

  Jernberg, Åsa Gustafsson ^a   Remberger, Mats ^a   Ringdén, Olle ^a   Winiarski, Jacek ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bone marrow transplantation; Children; Leukemia; Relapse; Risk factor; Survival; Unrelated

Indexed keywords

LEUKOCYTE ANTIGEN;

ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILD; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; RELAPSE; RISK FACTOR; SEX DIFFERENCE; STEM CELL TRANSPLANTATION;

CHILD; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; SEX FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 4644223290     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00175.x     Document Type: Article

References (57)

1. RIVERA GK, PINKEL D, SIMONE JV, HANCOCK ML, CRIST WM. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993: 329: 1289-1295.
2. REITER A, SCHRAPPE M, LUDWIG WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994: 84: 3122-3133.
3. CHESSELLS JM, BAILEY C, RICHARDS SM. Intensification of treatment and survival in all children with lymphoblastic leukemia: results of UK Medical Research Council trial UK-ALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 1995: 345: 143-148.
4. PUI CH. Childhood leukemias. N Engl J Med 1995: 332: 1618-1630.
5. GUSTAFSSON G, KREUGER A, CLAUSEN N, et al. Intensified treatment of acute childhood lymphoblastic leukemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998: 87: 1151-1161.
6. ARICO M, VALSECCHI MG, CAMITTA B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000: 342: 998-1006.
7. SANDERS JE, FLOURNOY N, THOMAS ED, et al. Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. Med Pediatr Oncol 1985: 13: 165-172.
8. BARRETT AJ, HOROWITZ MM, POLLOCK BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994: 331: 1253-1258.
9. UDERZO C, VALSECCHI MG, BACIGALUPO A, et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995: 13: 352-358.
10. WOODS WG, NEUDORF S, GOLD S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001: 97: 56-62.
11. BALDUZZI A, GOOLEY T, ANASETTI C, et al. Unrelated donor marrow transplantation in children. Blood 1995: 86: 3247-3256.
12. DAVIES SM, WAGNER JE, SHU XO, et al. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997: 15: 557-565.
13. GUSTAFSSON A, REMBERGER M, WINIARSKI J, RINGDEN O. Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting. Bone Marrow Transplant 2000: 25: 1059-1065.
14. HONGENG S, KRANCE RA, BOWMAN LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukemia. Lancet 1997: 350: 767-771.
15. OAKHILL A, PAMPHILON DH, POTTER MN, et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukemia in second complete remission. Br J Haematol 1996: 94: 574-578.
16. WOOLFREY AE, ANASETTI C, STORER B, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002: 99: 2002-2008.
17. OLERUP O, ZETTERQUIST H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992: 39: 225-235.
18. RINGDEN O, REMBERGER M, PERSSON U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995: 15: 619-625.
19. RINGDEN O, BACKMAN L, LONNQVIST B, et al. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986: 1: 41-51.
20. STORB R, DEEG HJ, WHITEHEAD J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986: 314: 729-735.
21. LJUNGMAN P, LORE K, ASCHAN J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996: 17: 583-587.
22. GLUCKSBERG H, STORB R, FEFER A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974: 18: 295-304.
23. SHULMAN HM, SULLIVAN KM, WEIDEN PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980: 69: 204-217.
24. WINIARSKI J, RINGDEN O, REMBERGER M, DALIANIS T, LJUNGMAN P, BORGSTROM B. Bone marrow transplantation in children using unrelated donors at Huddinge Hospital. Acta Paediatr 1996: 85: 327-335.
25. AL-KASIM FA, THORNLEY I, ROLLAND M, et al. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukemia in childhood: similar survival after matched-related and matched-unrelated donor transplants. Br J Haematol 2002: 116: 483-490.
26. BEATTY PG, HANSEN JA, LONGTON GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991: 51: 443-47.
27. BARRETT AJ, HOROWITZ MM, GALE RP, et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989: 74: 862-871.
28. BUNIN N, CARSTON M, WALL D, et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 2002: 99: 3151-3157.
29. GREINIX HT, NACHBAUR D, KRIEGER O, et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 2002: 117: 914-923.
30. DROBYSKI WR, KLEIN J, FLOMENBERG N, et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen- disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 2002: 99: 806-814.
31. CORNELISSEN JJ, CARSTON M, KOLLMAN C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001: 97: 1572-1577.
32. KOLLMAN C, HOWE CWS, ANASETTI C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001: 98: 2043-2051.
33. EISNER MD, AUGUST CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995: 15: 663-668.
34. FRASSONI F, LABOPIN M, GLUCKMAN E, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996: 17: 13-18.
35. NASH RA, PEPE MS, STORB R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992: 80: 1838-1845.
36. GALE RP, BORTIN MM, VAN BEKKUM DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987: 67: 397-06.
37. BOSTROM L, RINGDEN O, SUNDBERG B, LINDE A, TOLLEMAR J, NILSSON B. Pretransplant herpesvirus serology and acute graft-versus-host disease. Transplantation 1988: 46: 548-552.
38. GRATAMA JW, VD NAT H, WEILAND HT, et al. Intensification of GVHD prophylaxis interferes with the effects of pretransplant herpes virus serology on the occurrence of grades II-IV acute graft-versus-host disease. Ann Hematol 1992: 64 (Suppl): A137-A139.
39. PRZEPIORKA D, SMITH TL, FOLLODER J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999: 94: 1465-1470.
40. PETERSDORF EW, MICKELSON EM, ANASETTI C, MARTIN PJ, WOOLFREY AE, HANSEN JA. Effect of HLA mismatches on the outcome of hematopoietic transplants. Curr Opin Immunol 1999: 11: 521-526.
41. SZYDLO R, GOLDMAN JM, KLEIN JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997: 15: 1767-1777.
42. SIERRA J, STORER B, HANSEN JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997: 89: 4226-4235.
43. SMITH FO, KING R, NELSON G, et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukemia. Br J Haematol 2002: 116: 716-724.
44. GUSTAFSSON A, LEVITSKY V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000: 95: 807-814.
45. BRENNER M, ROSSIG C, SILI U, YOUNG JW, GOULMY E. Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. Hematology (Am Soc Hematol Educ Program) 2000: 356-375.
46. HOWS J, BRADLEY BA, GORE S, DOWNIE T, HOWARD M, GLUCKMAN E. Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 1993: 12: 371-380.
47. KERNAN NA, BARTSCH G, ASH RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993: 328: 593-602.
48. SPEISER DE, TIERCY JM, RUFER N, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996: 87: 4455-4462.
49. SAARINEN-PIHKALA UM, GUSTAFSSON G, RINGDEN O, et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001: 19: 3406-3414.
50. DAVIES SM, DEFOR TE, MCGLAVE PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001: 110: 339-346.
51. LAUSEN BF, HEILMANN C, VINDELOV L, JACOBSEN N. Outcome of acute lymphoblastic leukemia in Danish children after allogeneic bone marrow transplantation. Superior survival following transplantation with matched unrelated donor grafts. Bone Marrow Transplant 1998: 22: 325-330.
52. RINODEN O, HOROWITZ MM, SONDEL P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993: 81: 1094-1101.
53. ASCHAN J, RINGDEN O, SUNDBERG B, GAHRTON G, LJUNGMAN P, WINIARSKI J. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991: 7: 113-119.
54. HOROWITZ MM, GALE RP, SONDEL PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990: 75: 555-562.
55. WEIDEN PL, FLOURNOY N, THOMAS ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979: 300: 1068-1073.
56. RINGDEN O, HERMANS J, LABOPIN M, APPERLEY J, GORIN NC, GRATWOHL A. The highest leukemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 1996: 24: 71-79.
57. GUSTAFSSON JERNBERG A, REMBERGER M, RINGDEN O, WINIARSKI J. Graft-versus-leukemia effect in children: chronic GVHD has a significant impact on relapse and survival. Bone Marrow Transplant 2003: 31: 175-181.